Almirall predicts positive 2021 development of psoriasis product
Dermatology company Almirall retreated in 2020 due to generic competition and Covid-19-related challenges, but the firm expects progress in 2021, aided by two of the firm's newest products.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
In early 2020, already, Almirall warned this wouldn't be the best year. Competition from US generic products would have a severe impact, and the firm was facing a series of investments.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
